🇺🇸 FDA
Patent

US 10092656

Protease inhibitors having enhanced features

granted A61KA61K31/4402A61K31/4433

Quick answer

US patent 10092656 (Protease inhibitors having enhanced features) held by Nektar Therapeutics expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/4402, A61K31/4433, A61K31/635, A61K38/05